Page last updated: 2024-10-21

acemetacin and Obesity

acemetacin has been researched along with Obesity in 1 studies

acemetacin : A carboxylic ester that is the carboxymethyl ester of indometacin. A non-steroidal anti-inflammatory drug, it is used in the treatment of rheumatoid arthritis, osteoarthritis, and low back pain, as well as for postoperative pain and inflammation. Its activity is due to both acemetacin and its major metabolite, indometacin.

Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Toda, Y1
Kobayashi, T1

Trials

1 trial available for acemetacin and Obesity

ArticleYear
The usefulness of walking for preventing sarcopenia in dieting postmenopausal women complaining of knee pain.
    Annals of the New York Academy of Sciences, 2000, Volume: 904

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Appetite Depressants; Body Composition; Combined Moda

2000